The Effect of Pethidine Analgesia on Labor Duration and Maternal-Fetal Outcomes.
Journal
Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064
Informations de publication
Date de publication:
12 05 2021
12 05 2021
Historique:
received:
06
11
2020
accepted:
10
11
2020
entrez:
14
5
2021
pubmed:
15
5
2021
medline:
29
6
2021
Statut:
epublish
Résumé
Opioid analgesics had been used from time to time for treating labor pain. However, their use have been concerning. The aim of this study is to evaluate the effect of pethidine on duration of active phase of labor, labor pain and maternal-neonatal outcomes. In the present case-control study, the study group received a 50 mg pethidine intramuscular injection upon the start of active phase of labor, and the control group consisted of patients who receive placebo injeciton. In both groups, vital signs were measured before, and at 0, 5, 15, 30, 45 and 60 minutes after the injection. Pain intensity was evaluated with Visual Analogue Scale (VAS) prior to, and 1 hour and 2 hours after injection. Data regarding labor phase durations, maternal side effects, newborn APGAR scores and fetal respiratory problems were recorded. 102 patients in Pethidine group and 92 patients in control group, were included into the study. Labor pain VAS-scores were significantly lower in the study group (p<0.001). Moreover, active phase of labor duration was significantly shorter in the study group (p<0.001). Maternal pulse significantly decreased, and maternal nausea-vomiting was frequent in the study groups. However, the groups were similar in terms of other side effects and neonatal outcomes. Pethidine significantly reduces active phase of labor duration, has a favorable analgesic effect in treating labor pain and is not associated with serious maternal or neonatal complications. It is therefore considered an acceptable agent for use during active phase of labor.
Sections du résumé
BACKGROUND
Opioid analgesics had been used from time to time for treating labor pain. However, their use have been concerning. The aim of this study is to evaluate the effect of pethidine on duration of active phase of labor, labor pain and maternal-neonatal outcomes.
METHODS
In the present case-control study, the study group received a 50 mg pethidine intramuscular injection upon the start of active phase of labor, and the control group consisted of patients who receive placebo injeciton. In both groups, vital signs were measured before, and at 0, 5, 15, 30, 45 and 60 minutes after the injection. Pain intensity was evaluated with Visual Analogue Scale (VAS) prior to, and 1 hour and 2 hours after injection. Data regarding labor phase durations, maternal side effects, newborn APGAR scores and fetal respiratory problems were recorded.
RESULTS
102 patients in Pethidine group and 92 patients in control group, were included into the study. Labor pain VAS-scores were significantly lower in the study group (p<0.001). Moreover, active phase of labor duration was significantly shorter in the study group (p<0.001). Maternal pulse significantly decreased, and maternal nausea-vomiting was frequent in the study groups. However, the groups were similar in terms of other side effects and neonatal outcomes.
CONCLUSIONS
Pethidine significantly reduces active phase of labor duration, has a favorable analgesic effect in treating labor pain and is not associated with serious maternal or neonatal complications. It is therefore considered an acceptable agent for use during active phase of labor.
Identifiants
pubmed: 33988155
doi: 10.23750/abm.v92i2.10905
pmc: PMC8182611
doi:
Substances chimiques
Analgesics, Opioid
0
Meperidine
9E338QE28F
Banques de données
ClinicalTrials.gov
['NCT03882814']
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2021065Références
Br J Anaesth. 2002 Mar;88(3):374-8
pubmed: 11990269
Int J Gynaecol Obstet. 2012 Jul;118(1):7-10
pubmed: 22503494
Oman Med J. 2012 May;27(3):261-2
pubmed: 22811785
BJOG. 2015 Jun;122(7):983-92
pubmed: 25558983
BJOG. 2004 Jul;111(7):648-55
pubmed: 15198753
Can J Anaesth. 2012 Mar;59(3):246-54
pubmed: 22057875
Acta Biomed Ateneo Parmense. 2000;71 Suppl 1:397-400
pubmed: 11424777
Br J Obstet Gynaecol. 1979 Aug;86(8):598-606
pubmed: 497129
Ther Clin Risk Manag. 2011;7:495-500
pubmed: 22241946
Ann Saudi Med. 2003 Sep-Oct;23(5):318-20
pubmed: 16868406
Best Pract Res Clin Obstet Gynaecol. 2010 Jun;24(3):289-302
pubmed: 20005180
J Matern Fetal Neonatal Med. 2016;29(11):1773-6
pubmed: 26135762
Zentralbl Gynakol. 1992;114(11):551-4
pubmed: 1481587
Cochrane Database Syst Rev. 2018 Jun 05;6:CD007396
pubmed: 29870574
Indian J Anaesth. 2010 Sep;54(5):400-8
pubmed: 21189877
Br J Obstet Gynaecol. 1996 Oct;103(10):968-72
pubmed: 8863693
Ginekol Pol. 2012 May;83(5):357-62
pubmed: 22708333
Eur J Obstet Gynecol Reprod Biol. 2018 Sep;228:197-202
pubmed: 29990827
Midwifery. 2014 Jan;30(1):36-42
pubmed: 23523191
Oman Med J. 2013 Sep;28(5):306-10
pubmed: 24044055
Int J Gynaecol Obstet. 2003 Jul;82(1):11-6
pubmed: 12834936
Midwifery. 2017 Oct;53:15-19
pubmed: 28735031
Br J Anaesth. 2010 Feb;104(2):209-15
pubmed: 20008859